NASDAQ:RZLT Rezolute Q4 2026 Earnings Results & Report $4.01 +0.43 (+12.01%) Closing price 04:00 PM EasternExtended Trading$4.01 +0.00 (+0.10%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rezolute missed analyst earnings expectations in its Q4 2026 results, released September 24, 2026. The company reported EPS of -$0.20 versus the -$0.1479 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Report DateSeptember 24, 2026TimeAfter Market ClosesConference Call4:00 PM ET Rezolute EPS ResultsActual EPS-$0.20Consensus EPS -$0.1479Beat/MissMissed by -$0.0522One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersRezolute Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Rezolute Q4 2026 Earnings FAQ Did Rezolute beat earnings estimates for Q4 2026? Rezolute (NASDAQ:RZLT) reported earnings of -$0.20 per share for Q4 2026, missing the consensus estimate of -$0.1479. The report was announced on Thursday, September 24, 2026. Rezolute Earnings HeadlinesRezolute reports phase 3 upLIFT study meets primary efficacy endpoint in tumor hyperinsulinismNovember 13, 2026 | msn.comRezolute stock rises on positive Phase 3 upLIFT trial resultsNovember 13, 2026 | finance.yahoo.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 17 at 1:00 AM | Behind the Markets (Ad)Rezolute Reports Positive Phase 3 Results For Ersodetug; Prices $100M OfferingNovember 13, 2026 | rttnews.comRezolute Announces Preliminary Positive Phase 3 upLIFT Results for Ersodetug in Tumor Hyperinsulinism November 13, 2026 | quiverquant.comQRezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNovember 13, 2026 | globenewswire.comSee More Rezolute Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email. Email Address About RezoluteRezolute (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia. Rezolute is led by CEO Nevan Elam. Its drug candidates remain in development and are not approved treatments.View Rezolute ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.